Showing 3251-3260 of 5621 results for "".
- New Mobile Platform Records Patient Outcomes After Cataract Surgeryhttps://modernod.com/news/new-mobile-platform-records-patient-outcomes-after-cataract-surgery/2476543/Rayner has developed RayPRO, a mobile phone and web-based app for collecting patient-reported outcomes (PROs) for 3 years after surgery. The company says this is the first time such software has been available for free to ophthalmic surgeons. It is a bespoke platform that has been specific
- Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents vs. Topical Prostaglandinhttps://modernod.com/news/trial-highlights-5-year-performance-of-2-standalone-glaukos-istents-vs-topical-prostaglandin/2476466/Glaukos announced that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35.3% reduction in mean IOP to 16.5 mmHg
- IStent Inject Device Lowers IOP After Cataract Surgery in Glaucoma Patientshttps://modernod.com/news/istent-inject-device-lowers-iop-after-cataract-surgery-in-glaucoma-patients/2476438/In patients with mild to moderate glaucoma and cataract, the second-generation iStent inject system, with two redesigned stents, reduces IOP more than cataract surgery alone, according to results of a new pivotal trial, as reported by Reut
- Topcon Unveils New Maestro Unlimited OCT System at VEE 2019https://modernod.com/news/topcon-to-present-new-solution-for-oct-and-data-management-at-vee-2019/2476407/Topcon showcased several innovative new offerings at the Vision Expo East (VEE) conference in New York City. Topcon unveiled the new Maestro Unlimited, which pairs the Maestro 3D OCT with the new Topcon Harmony, a web-based data management application that provides unlimited device connect
- VisionCare Announces Regulatory Approval of the CentraSight Treatment Program in Australiahttps://modernod.com/news/visioncare-announces-regulatory-approval-of-the-centrasight-treatment-program-in-australia/2476395/VisionCare announced that the Australian Department of Health Therapeutic Goods Administration has issued a Therapeutic Goods Certificate to the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), approving it for the improvement of visual acuity in patients who are 55 years and older with b
- Glaukos: Study Confirms Long-Term Efficacy and Safety Profile of iStent in Combination with Cataract Surgeryhttps://modernod.com/news/study-confirms-long-term-efficacy-and-safety-profile-of-glaukos-istent-in-combination-with-cataract-surgery/2476375/Glaukos announced that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean IOP to 14.7 mmHg after 5 years of follow-up. The
- Roche/Genentech Study Shows First-Time Proof That AI Can Detect Severity of DMEhttps://modernod.com/news/roche-genentech-study-shows-first-time-proof-that-ai-can-detect-severity-of-dme/2476347/A new study published in the journal
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel
- Roche Acquires Spark Therapeutics in $4.8 Billion Dealhttps://modernod.com/news/roche-acquires-spark-therapeutics-in-4-3-billion-deal/2476268/Swiss pharma giant Roche acquired and Philadelphia-based gene therapy company Spark Therapeutics in an all cash transaction worth $4.8 billion, or $114.50 per share. The merger has been unanimously approved by the boards of Spark Therap
- New US Experiments Aim To Create Gene-Edited Human Embryoshttps://modernod.com/news/new-us-experiments-aim-to-create-gene-edited-human-embryos/2476330/A scientist in New York is conducting experiments designed to modify DNA in human embryos as a step toward someday preventing inherited diseases, according to an NPR